Cargando…
A randomized controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA point mutations
BACKGROUND: Increasing clarithromycin resistance has led to changes in several guidelines for treatment of Helicobacter pylori infections. We compared the H. pylori eradication rates of the empirical concomitant therapy (CoT) and a tailored therapy (TaT) using dual-priming oligonucleotide-based poly...
Autores principales: | Kim, Su Jin, Jee, Sam Ryong, Park, Moo In, Jung, Kyoungwon, Kim, Gwang Ha, Lee, Moon Won, Lee, Jin, Jang, Jin Seok, Koh, Myeongseok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387952/ https://www.ncbi.nlm.nih.gov/pubmed/35984159 http://dx.doi.org/10.1097/MD.0000000000030069 |
Ejemplares similares
-
Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients
por: Choi, Youn I, et al.
Publicado: (2021) -
Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection
por: Perkovic, Nikola, et al.
Publicado: (2021) -
Comparing the Efficacy of Concomitant Therapy with Sequential Therapy as the First-Line Therapy of Helicobacter pylori Eradication
por: Jung, Sung Min, et al.
Publicado: (2016) -
Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes
por: Kim, Sung Eun, et al.
Publicado: (2017) -
Role of Tegoprazan in Helicobacter pylori Eradication Therapy
por: Lee, Jin
Publicado: (2022)